Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Pfizer    PFE

PFIZER (PFE)
My previous session
Most popular
  Report  
Real-time Quote. Real-time Cboe BZX - 08/14 05:57:17 pm
40.545 USD   -0.65%
10:07aBIOCENTURY - MA : FDA, Allergan
AQ
08/13Alnylam gets first RNAi drug approved
AQ
08/10GEMPHIRE THERAP : Shares Fall Over 50% in Heavy Trading -- Market Mo..
DJ
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
08/07/2018 08/08/2018 08/09/2018 08/10/2018 08/14/2018 Date
40.84(c) 41.41(c) 41(c) 40.93(c) 40.605 Last
17 958 832 24 513 719 19 090 378 17 261 979 6 507 143 Volume
-0.49% +1.40% -0.99% -0.17% -0.50% Change
More quotes
Financials (USD)
Sales 2018 54 193 M
EBIT 2018 20 582 M
Net income 2018 13 122 M
Debt 2018 24 897 M
Yield 2018 3,36%
Sales 2019 55 280 M
EBIT 2019 21 379 M
Net income 2019 13 825 M
Debt 2019 17 053 M
Yield 2019 3,56%
P/E ratio 2018 18,19
P/E ratio 2019 16,66
EV / Sales2018 4,88x
EV / Sales2019 4,64x
Capitalization 239 B
More Financials
Company
Pfizer Inc. engages in the discovery, development, and manufacture of healthcare products specializes in medicines, vaccine, and consumer healthcare.It operates through the Pfizer Innovative Health (IH) and Pfizer Essential Health (EH) segments.The IH segment focuses on the development and... 
Sector
Pharmaceuticals
Calendar
08/27Presentation
More about the company
Surperformance© ratings of Pfizer
Trading Rating : Investor Rating :
More Ratings
Latest news on PFIZER
10:07aBIOCENTURY - MANAGEMENT TRACKS : FDA, Allergan
AQ
08/13Alnylam gets first RNAi drug approved
AQ
08/10GEMPHIRE THERAPEUTICS : Shares Fall Over 50% in Heavy Trading -- Market Mover
DJ
08/10ANTARES PHARMA : Enters into a Development Agreement with Pfizer INC
AQ
08/10GEMPHIRE THERAPEUTICS : Announces Amended and Restated Gemcabene License Agreeme..
AQ
08/10CARA THERAPEUTICS : Appoints Christopher A. Posner to Board of Directors
AQ
08/10Antares Pharma Reports Second Quarter 2018 Operating and Financial Results
AQ
08/10PFIZER : NICE changes its mind on Pfizers Besponsa
AQ
08/10PFIZER : NICE okays Pfizer blood cancer drug Besponsa after appeal
AQ
08/09PFIZER : Receives European Approval for Oncology Biosimilar, TRAZIMERA™ tr..
AQ
More news
Sector news : Pharmaceuticals - NEC
04:21pDAVID EINHORN : Billionaire Investor David Einhorn Hit In Monsanto Ruling
DJ
04:15pTSX advances as oil prices boost energy stocks
RE
11:47aNOVARTIS : recruits new compliance head from Siemens after ethics stumbles
RE
11:04aEXCLUSIVE : Carlyle starts preparations for $5 billion listing of chemicals grou..
RE
08:48aBAYER : Verdict In Weed Killer Case Hits Bayer -- WSJ
DJ
More sector news : Pharmaceuticals - NEC
MarketScreener Strategies on PFIZER 
PFIZER INC. - 2016
Expectation of a turn-around
BUY
PFIZER INC. - 2016
Back on a long term support level
BUY
More Strategies
Latest Tweets
03:50pWhat are clinical trials? Meet the Cure Hunters.
4
03:49pHow does Medical Affairs get the most value out of RWE? Pfizer and Novartis p.. 
07:29aJoshLia’s take on being called young John Lloyd Cruz, Claudine Barretto | @CA..
40
08/13Alnylam Gets An FDA Nod — But Pfizer, Others May Decimate It
2
08/13Top 3 today -- Back to the beginning: Pfizer seeds discovery-stage neuro star.. 
More tweets
Qtime:555
News from SeekingAlpha
10:35aSPARK THERAPEUTICS : This Appears To Be A Dip Worth Buying 
08/13A Quality Driven Dividend Growth Portfolio - Pfizer Inc 
08/133 THINGS IN BIOTECH, AUGUST 13 : Rare Disease Approvals And Other Forward Moment.. 
08/12S&P 500 : It's All In The Numbers And The Numbers Never Lie 
08/11Eli Lilly Is An Attractive Buy For 2018 
Chart PFIZER
Duration : Period :
Pfizer Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PFIZER
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 40,8 $
Spread / Average Target -0,02%
EPS Revisions
Managers
NameTitle
Ian C. Read Chairman & Chief Executive Officer
Albert Bourla Chief Operating Officer & Director
Frank A. D'Amelio Chief Financial Officer & EVP-Business Operations
Freda C. Lewis-Hall Chief Medical Officer & Executive Vice President
W. Don Cornwell Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
PFIZER13.00%239 423
JOHNSON & JOHNSON-6.42%350 770
NOVARTIS-0.87%209 596
ROCHE HOLDING LTD.-3.39%207 317
MERCK AND COMPANY17.42%175 715
AMGEN11.80%125 843